First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a 2 part, multi-center, open-label, First-in-Human clinical study to evaluate the
safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of INT-1B3 in the
treatment of patients with advanced solid tumors.